Abstract
Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending
doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall
clinical status, and quality of life will be measured as secondary endpoints in this
open-label study.
